醫藥股受捧 國藥、百濟、君實、諾誠健華、康方、金斯瑞及信達生物漲5%-9%
阿思達克 09-11 15:14
內地8月人民幣新增貸款達1.36萬億元人民幣(下同)，高於市場預期1.25萬億元。此外，今天於北京召開全國外匯市場自律機制專題會議強調，堅決防範匯率超調風險，並表明對人民幣匯率「該出手時就出手」。在岸和離岸人民幣兌美元中午曾抽升逾700點子。滬指及深成午後升幅曾擴至1.2%-1.6%，高見3,155及10,443，收3,142及10,382，回升0.8%及1%。板塊方面以醫藥生物最強，曾漲逾3%，收市仍升近2.9%。
本港藍籌醫藥相關股全面逆市造好，尤其是國藥(01099.HK)回升5%報22.05元，股價重越20天線(21.8元)；翰森製藥(03692.HK)反覆回升3.8%報10.46元，股價重越20天及10天線(10.25元)。石藥(01093.HK)、藥明生物(02269.HK)及中生製藥(01177.HK)回升逾1.5%-3%，後兩者跑贏分別報42.8元及3.01元，回升2.3%及3%。此外，京東健康(06618.HK)及阿里健康(00241.HK)回升3%及4.9%，報42.6元及4.68元。
非藍籌藥股以信達生物(01801.HK)表現最好，股價續漲近9%曾高見38.9元，創逾三個月高。百濟神州(06160.HK)、君實生物(01877.HK)、諾誠健華-B(09969.HK)、康方生物-B(09926.HK)及金斯瑞生物(01548.HK)升逾5%-7%，股價曾分別高見129.6元、21.35元、6.48元、37.2元及19.64元。
藥明康德(02359.HK)、神威藥業(02877.HK)、先聲藥業(02096.HK)、科濟藥業-B(02171.HK)及康希諾(06185.HK)升逾2%。
恆指繼今早在地產分類指數股曾急挫4.5%、友邦(01299.HK)和港交所(00388.HK)曾續挫4.7%及4.3%，以及新經濟股續弱拖累，曾挫359點或2%低見17,842獲承接，下午收窄跌幅高見18,100，現報18,035，僅續跌166點或0.9%，總成交額1,032億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
More Content
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
